Mustafa Saleh

Did you catch the live visual notes at KCRS25? Artist Ryan from Ink Factory Studio captured the heart of each session with creativity and serious skill. Thanks for helping us see the impact of #kidneycancer research in a whole new way! #KCRS25 #AcceleratingCures

Behind every data point is a story. Every bar, every dot, represents a patient. Let’s never forget the human side of science. #KCRS25 #KidneyCancer @OncoAlert @kidneycan @urotoday @ASCO @DrChoueiri @advocatekidneys @IKCCorg @Uromigos

Some of my favorite (non exhaustive list) people presenting their work at #KCRS25 - a thread You can find the poster and e-poster abstracts online, some hidden gems there @OncoAlert

This is Thomas Seyfried. He’s a professor of biology, who’s studied cancer for 30+ years. His message? Cancer isn’t bad genes or bad luck—it’s damaged mitochondria. This flips everything you’ve been told about how to treat & prevent cancer:

Another conference, another poster, this time at #KCRS25. Discussing intra tumoral viral signature association with RCC immune phenotypes and clinical outcomes.

ncRCC real-world data from 13,909 patients! Attrition remains high. @Huntsman_GU @neerajaiims @umangtalking @ziremozay @kidneycan #kidneycancer

@Clara__Steiner 🧬 Plasma proteomics reveals a unique mitochondrial signature in chromophobe RCC! #KidneyCancer #PrecisionOncology @DanaFarber @BrighamWomens @DrChoueiri @LisaHenske @VincentWenxinXu @kidneycan

Thank you @CJSTRAV3 @kidneycan

That's a wrap on #KCRS25! Thank you to everyone who joined us, whether you were with us in Boston or tuning in virtually from around the world. Your presence, questions, and passion for collaboration made this year’s summit one to remember. Until next time, keep pushing the…

Rocking the stage @MarcMachaalani with his work on KIM-1 levels in JAVELINE 101 trial: 1. Patients with higher levels of KIM1 at baseline worse OS, PFS. 2. KIM 1 levels associated with BAP1 and proliferative signature. 3. KIM1 + IMDC + change in KIM1 achieved an AUC of 0.76

Big sis @NazliDizman presented an innovative trial evaluating the first bispecific PDL1/VEGF targeting agent Always one step ahead! Looking forward to seeing results! @OncoAlert

Powerful words @CJSTRAV3 about the importance of research funding and continuous efforts, with the goal of improving patient outcomes @kidneycan #KCRS25

Exciting talk by @BraunMDPhD at #KCRS2025 on not only the feasibility of personalized neoantigen vaccines in #kidneycancer , but also preclinical evidence of T cell response & preliminary promising clinical activity 💉🧬 @kidneycan @urotoday @OncoAlert

Here we go. All eyes on kidney cancer research in Boston for 2 days.

I wrote a little bit about a cool recent paper looking at heritability estimates from very large registry data, and how we still really don't understand why outcomes track in families. A short 🧵:

1/ Happy to share our latest piece in @Nature_NPJ precision oncology: "Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer". Work co-led with @KarlSemaan with great mentorship from @Jberchuck @SylvanBacaLab #MattFreedman @DrChoueiri…

Every morning. The power of hope and the hope of cure @DanaFarber and @TheJimmyFund

1/ Thrilled to share our work on Chromophobe RCC (ChRCC) and Renal Oncocytic Neoplasms (RONs) out @JCO_ASCO !!! Incredibly thankful to my mentors @BraunMDPhD @DrChoueiri @VanAllenLab and all co-authors @DanaFarber @BIDMC_IM @Yale @BrighamWomens Link: ascopubs.org/doi/10.1200/JC…

As the waves 🌊 settle after #ASCO25 we @DanaFarber_GU take a deeper dive 🤿 into the most impactful data! Join @DrChoueiri @BradMcG04 @AtishChoudhury as we discuss what we learned & where we’re going next! Prostate 🔗 youtu.be/heLQLuWjlzM Bladder 🔗…

I’m not “riding my bike” this year ….but still raising funds for the @PanMass Challenge ! Everyone can have an impact to cure cancer @DanaFarber Link: profile.pmc.org/TC0306